132 related articles for article (PubMed ID: 10427622)
41. Immunoadsorption therapy for Fisher syndrome associated with IgG anti-GQ1b antibody.
Ohtsuka K; Nakamura Y; Tagawa Y; Yuki N
Am J Ophthalmol; 1998 Mar; 125(3):403-6. PubMed ID: 9512167
[TBL] [Abstract][Full Text] [Related]
42. Interleukin-4 protects against a genetically linked lupus-like autoimmune syndrome.
Santiago ML; Fossati L; Jacquet C; Müller W; Izui S; Reininger L
J Exp Med; 1997 Jan; 185(1):65-70. PubMed ID: 8996242
[TBL] [Abstract][Full Text] [Related]
43. [The distribution and clinical significance of IgG subclasses of anti-glomerular basement membrane antibodies].
Yan Y; Cui Z; Zhao MH
Beijing Da Xue Xue Bao Yi Xue Ban; 2004 Oct; 36(5):501-4. PubMed ID: 15489931
[TBL] [Abstract][Full Text] [Related]
44. Glomerular expression of large polyomavirus T antigen in binary tet-off regulated transgenic mice induces apoptosis, release of chromatin and initiates a lupus-like nephritis.
Bendiksen S; Mortensen ES; Olsen R; Fenton KA; Kalaaji M; Jørgensen L; Rekvig OP
Mol Immunol; 2008 Feb; 45(3):728-39. PubMed ID: 17719634
[TBL] [Abstract][Full Text] [Related]
45. High titer anti-basement membrane antibodies in a subset of patients with pediatric systemic lupus erythematosus.
Orjuela A; Suwanichkul A; Canter D; Minard CG; Devaraj S; Hicks MJ; Muscal E; Wenderfer SE
Am J Nephrol; 2015; 41(3):241-7. PubMed ID: 25926050
[TBL] [Abstract][Full Text] [Related]
46. Mercuric chloride induced autoimmune disease in Brown-Norway rats: sequential search for anti-basement membrane antibodies and circulating immune complexes.
Bellon B; Capron M; Druet E; Verroust P; Vial MC; Sapin C; Girard JF; Foidart JM; Mahieu P; Druet P
Eur J Clin Invest; 1982 Apr; 12(2):127-33. PubMed ID: 6212254
[TBL] [Abstract][Full Text] [Related]
47. The effect of immunoadsorption therapy by a protein A column on patients with thrombocytopenia.
Muroi K; Sasaki R; Miura Y
Semin Hematol; 1989 Apr; 26(2 Suppl 1):10-4. PubMed ID: 2658094
[TBL] [Abstract][Full Text] [Related]
48. Heterogeneity of immune complex-derived anti-DNA antibodies associated with lupus nephritis.
Sasaki T; Hatakeyama A; Shibata S; Osaki H; Suzuki M; Horie K; Kitagawa Y; Yoshinaga K
Kidney Int; 1991 Apr; 39(4):746-53. PubMed ID: 2051733
[TBL] [Abstract][Full Text] [Related]
49. Treatment with dsDNA-anti-dsDNA antibody complexes extends survival, decreases anti-dsDNA antibody production and reduces severity of nephritis in MRLlpr mice.
Burny W; Lebrun P; Cosyns JP; Saint-Remy JM
Lupus; 1997; 6(1):4-17. PubMed ID: 9116717
[TBL] [Abstract][Full Text] [Related]
50. Differential characteristics of immune-bound antibodies in diffuse proliferative and membranous forms of lupus glomerulonephritis.
Roberts JL; Wyatt RJ; Schwartz MM; Lewis EJ
Clin Immunol Immunopathol; 1983 Nov; 29(2):223-41. PubMed ID: 6605223
[TBL] [Abstract][Full Text] [Related]
51. The course of anticardiolipin antibody levels under immunoadsorption therapy.
Hauser AC; Hauser L; Pabinger-Fasching I; Quehenberger P; Derfler K; Hörl WH
Am J Kidney Dis; 2005 Sep; 46(3):446-54. PubMed ID: 16129206
[TBL] [Abstract][Full Text] [Related]
52. Clinical significance of anti-dsDNA antibody isotypes: IgG/IgM ratio of anti-dsDNA antibodies as a prognostic marker for lupus nephritis.
Förger F; Matthias T; Oppermann M; Becker H; Helmke K
Lupus; 2004; 13(1):36-44. PubMed ID: 14870916
[TBL] [Abstract][Full Text] [Related]
53. In vitro removal of anti-HLA IgG antibodies from highly sensitized transplant recipients by immunoadsorption with protein A and protein G sepharose columns: a comparison.
Barocci S; Nocera A
Transpl Int; 1993 Jan; 6(1):29-33. PubMed ID: 8452629
[TBL] [Abstract][Full Text] [Related]
54. Immunoadsorption, current status and future developments.
Braun N; Bosch T
Expert Opin Investig Drugs; 2000 Sep; 9(9):2017-38. PubMed ID: 11060790
[TBL] [Abstract][Full Text] [Related]
55. Immunosuppressor control as a modality of cancer treatment: effect of plasma adsorption with Staphylococcus aureus protein A.
Ray PK
Contemp Top Immunobiol; 1985; 15():147-211. PubMed ID: 3161699
[TBL] [Abstract][Full Text] [Related]
56. Effective treatment of experimental lupus nephritis by combined administration of anti-CD11a and anti-CD54 antibodies.
Kootstra CJ; Van Der Giezen DM; Van Krieken JH; De Heer E; Bruijn JA
Clin Exp Immunol; 1997 May; 108(2):324-32. PubMed ID: 9158106
[TBL] [Abstract][Full Text] [Related]
57. Correlations of C1q- and C3d-bearing circulating immune complexes with immunopathological disease activity in lupus nephritis patients.
Muso E; Yashiro M; Ito Y; Yoshida H; Sasayama S
Nihon Jinzo Gakkai Shi; 1994 Apr; 36(4):345-54. PubMed ID: 8022107
[TBL] [Abstract][Full Text] [Related]
58. Sialylated Autoantigen-Reactive IgG Antibodies Attenuate Disease Development in Autoimmune Mouse Models of Lupus Nephritis and Rheumatoid Arthritis.
Bartsch YC; Rahmöller J; Mertes MMM; Eiglmeier S; Lorenz FKM; Stoehr AD; Braumann D; Lorenz AK; Winkler A; Lilienthal GM; Petry J; Hobusch J; Steinhaus M; Hess C; Holecska V; Schoen CT; Oefner CM; Leliavski A; Blanchard V; Ehlers M
Front Immunol; 2018; 9():1183. PubMed ID: 29928274
[TBL] [Abstract][Full Text] [Related]
59. Circulating levels of chromatin fragments are inversely correlated with anti-dsDNA antibody levels in human and murine systemic lupus erythematosus.
Jørgensen MH; Rekvig OP; Jacobsen RS; Jacobsen S; Fenton KA
Immunol Lett; 2011 Aug; 138(2):179-86. PubMed ID: 21530588
[TBL] [Abstract][Full Text] [Related]
60. Subclasses of immunoglobulins and autoantibodies in autoimmune diseases.
Outschoorn I; Rowley MJ; Cook AD; Mackay IR
Clin Immunol Immunopathol; 1993 Jan; 66(1):59-66. PubMed ID: 8440074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
